Loading clinical trials...
Loading clinical trials...
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma; a Multi-center, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study
Conditions
Interventions
Holmium-166 radioembolization
Locations
1
Netherlands
UMC Utrecht
Utrecht, Netherlands
Start Date
March 1, 2022
Primary Completion Date
November 1, 2024
Completion Date
November 1, 2025
Last Updated
November 10, 2022
NCT06707233
NCT05911633
NCT06187961
NCT06561399
NCT04224636
NCT06397222
Lead Sponsor
UMC Utrecht
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions